Safety Profile of Niraparib as Maintenance Therapy for Ovarian Cancer: A Systematic Review and Meta-Analysis

Background: Patients with epithelial ovarian cancer (EOC), treated with niraparib maintenance, present with haematological and gastrointestinal toxicities. Limited data exist on niraparib safety assessment. Objective: To evaluate niraparib safety profile, as maintenance therapy, in women with platin...

Full description

Bibliographic Details
Main Authors:	Antonia Pagkali, Ioannis Mamais, Adamantios Michalinos, Aris P. Agouridis
Format:	Article
Language:	English
Published:	MDPI AG 2022-01-01
Series:	Current Oncology
Subjects:	niraparib maintenance therapy safety profile meta-analysis ovarian cancer randomised controlled trials
Online Access:	https://www.mdpi.com/1718-7729/29/1/29

Similar Items

Case Report: Niraparib as Maintenance Therapy in A Patient With Ovarian Carcinosarcoma
by: Jie Qing Zhang, et al.
Published: (2021-12-01)

Cost-effectiveness of maintenance niraparib with an individualized starting dosage in patients with platinum-sensitive recurrent ovarian cancer in China
by: Yin Shi, et al.
Published: (2023-07-01)

The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China
by: Jing Ni, et al.
Published: (2021-05-01)

The Development and Testing of a Patient Decision Aid for Individuals with Homologous Recombinant Proficient Ovarian Cancer Who Are Considering Niraparib Maintenance Therapy
by: Laura Hopkins, et al.
Published: (2024-03-01)

A phase 1 evaluation of the safety and tolerability of niraparib in combination with everolimus in advanced ovarian and breast cancers
by: David Starks, et al.
Published: (2023-09-01)

Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China
by: Jing Nie, et al.
Published: (2023-01-01)

Feasibility Study of a Network Meta-Analysis and Unanchored Population-Adjusted Indirect Treatment Comparison of Niraparib, Olaparib, and Bevacizumab as Maintenance Therapies in Patients with Newly Diagnosed Advanced Ovarian Cancer
by: Domenica Lorusso, et al.
Published: (2022-03-01)

Niraparib and Advanced Ovarian Cancer: A Beacon in the Non-BRCA Mutated Setting
by: Mauro Francesco Pio Maiorano, et al.
Published: (2023-09-01)

Niraparib-induced STAT3 inhibition increases its antitumor effects
by: Qianqian Zhao, et al.
Published: (2022-10-01)

Efficacy of oral ferric citrate hydrate treatment for anemia caused by niraparib: a case report
by: Hiroshi Kobayashi, et al.
Published: (2022-11-01)

A case of niraparib PARP-Inhibitor induced Sweet Syndrome in gynecologic cancer
by: Nora Badiner, et al.
Published: (2023-04-01)

Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy
by: Giorgio Valabrega, et al.
Published: (2021-04-01)

Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway
by: Entaz Bahar, et al.
Published: (2021-04-01)

Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives – a review
by: Sudeep Gupta, et al.
Published: (2019-11-01)

Successful Treatment of a Patient With Brain Metastasis From Ovarian Cancer With BRCA Wild Type Using Niraparib: A Case Report and Review of the Literature
by: Zhenhua Zhang, et al.
Published: (2022-04-01)

Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer
by: Yifan Jiang, et al.
Published: (2020-07-01)

The latest first-line treatment options for ovarian cancer: focus on maintenance therapy
by: A. A. Rumyantsev
Published: (2020-12-01)

Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer
by: Jinyu Meng, et al.
Published: (2021-10-01)

Comparative Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Ovarian Cancer: A Systematic Review and Network Meta-Analysis
by: Jing Luo, et al.
Published: (2022-06-01)

Use of First-Line PARP Inhibitors in Ovarian Cancer
by: Ursula Hasler-Strub
Published: (2020-11-01)

Short-term starvation synergistically enhances cytotoxicity of Niraparib via Akt/mTOR signaling pathway in ovarian cancer therapy
by: Wang Zhi, et al.
Published: (2022-01-01)

Efficacy and Safety of Placebo During the Maintenance Therapy of Ovarian Cancer in Randomized Controlled Trials: A Systematic Review and Meta-analysis
by: Jin-feng Wang, et al.
Published: (2022-05-01)

The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review
by: Chien-Hui Lau, et al.
Published: (2022-07-01)

Comprehensive Genomic Profiling-Guided Niraparib Treatment of Triple-Negative Breast Cancer in a Patient With Extensive Brain Metastasis: Case Report and Literature Review
by: Tai-Chung Lam
Published: (2021-02-01)

Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study
by: Valentina Tuninetti, et al.
Published: (2023-02-01)

Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer
by: Jiang X, et al.
Published: (2019-05-01)

Real‐world data of poly (ADP‐ribose) polymerase inhibitor response in Japanese patients with ovarian cancer
by: Ryosuke Uekusa, et al.
Published: (2024-04-01)

What predicts the clinical benefits of PARP inhibitors in platinum-sensitive recurrent ovarian cancer: A real-world single-center retrospective cohort study from China
by: Depu Zhang, et al.
Published: (2022-08-01)

Incidence and risk of hypertension associated with PARP inhibitors in cancer patients: a systematic review and meta-analysis
by: Xiu Chen, et al.
Published: (2023-01-01)

Radiopharmaceutical Switch Maintenance for Relapsed Ovarian Carcinoma
by: Charles A. Kunos, et al.
Published: (2020-09-01)

Exploration of chemotherapy-free regimen after multi-line chemotherapy-induced renal impairment in recurrent ovarian cancer: Case report and literature review
by: Liu-ping Zhang, et al.
Published: (2023-01-01)

Primary fallopian tube cancer followed by primary breast cancer in RAD51C mutation carrier treated with niraparib as first line maintenance therapy: a case report
by: Hua Yuan, et al.
Published: (2024-02-01)

LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring
by: Giovanni Canil, et al.
Published: (2023-05-01)

Plum supplementation and lipid profile: a systematic review and meta-analysis of randomised controlled trials
by: Moein Askarpour, et al.
Published: (2023-01-01)

IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation
by: Taigo Kato, et al.
Published: (2022-12-01)

Positive response to niraparib in chemo-refractory patients with metastatic appendiceal mucinous adenocarcinoma harboring ATM mutations: A case report
by: Junhui Wang, et al.
Published: (2023-02-01)

Clinical Benefit of Niraparib to TKI/mTORi-Resistance Metastatic ccRCC With BAP1-Frame Shift Mutation: Case Report and Literature Review
by: Bi-Jun Lian, et al.
Published: (2022-07-01)

PARP Inhibitors: Strategic Use and Optimal Management in Ovarian Cancer
by: Nicholas Hirschl, et al.
Published: (2024-02-01)

PARP inhibitor era in ovarian cancer treatment: a systematic review and meta-analysis of randomized controlled trials
by: István Baradács, et al.
Published: (2024-02-01)

Partial response to niraparib in combination with tislelizumab in a patient with metastatic undifferentiated tonsillar carcinoma: a case report and literature review
by: Jing Zhang, et al.
Published: (2023-05-01)